Medigene announced on 4 April 2019 that the company will partner with Cytovant Sciences (Cytovant), a biopharmaceutical company launched by Roivant Sciences and Sinovant Sciences focused on developing and commercializing innovative cellular therapeutics in Asia.
Medigene has granted Cytovant exclusive licenses to develop, manufacture, and commercialise Medigene’s research-stage T cell immunotherapy for the treatment of cancer and a dendritic cell (DC) vaccine in Greater China, South Korea, and Japan.
Cytovant and Medigene have also entered into a strategic collaboration and discovery agreement for T-cell receptor (TCR) immunotherapies for two additional products.
In addition to an upfront payment of $10m, Medigene reveals it may receive development, regulatory, and commercial milestone payments that could total up to $1bn for all four products across multiple indications.
Medigene will also earn royalty payments on net sales of the products in a low double-digit percentage range in relevant countries. All R&D costs incurred by Medigene within the collaboration will be reimbursed by Cytovant.